Companies Directory

Xenith IP Group Limited, (ASX: XIP) one of Australias largest intellectual property services groups, provides industry leading depth in traditional IP services in conjunction with a uniquely comprehensive suite of complementary advisory services along the innovation pathway. The Groups core business is to provide a range of IP services, including identification, registration, management, commercialisation, valuation and enforcement of IP rights. Xenith IP is made up of specialist IP firms Shelston IP, Griffith Hack and Watermark, and complementary services firm Glasshouse Advisory and employs more than 400 staff, including approximately 175 IP professionals (patent attorneys, trade mark attorneys and IP lawyers along with experts in specialist IP Advisory Services with expertise in the accounting, legal and finance disciplines) in Sydney, Melbourne, Brisbane and Perth. With an agile approach and flexible structure, Xenith IP brings the best people, systems and thinking seamlessly together, to deliver world class services that enable our clients to leverage greater opportunity from their technologies, brands and intangible assets. We think more broadly, more deeply and more holistically about innovation and IP, to maximise value and competitive advantage for our clients. Providing services across Australia, New Zealand, Asia, the US and Europe to an extensive client base made up of large multinational companies, universities and research groups, start-up firms and solo inventors. The Group also works with an extensive network of international associate IP firms.

Xennial is a marketing consultancy firm located in Auckland offering tailored marketing support to New Zealand businesses. Our approach to working with clients is both personable and 100% needs-based. As independent, multi-disciplinary marketers, Xennial will only ever recommend strategies and actions that are right for your business and geared towards success. Working with our Principal Consultants James Smith and Melissa Harris, youll have affordable expert marketing support at hand to guide and assist you and ensure your business reaches its full marketing potential. Whether you are looking for strategic direction or ongoing support to help you devise and execute activities professionally, Xennial can provide a tailored solution thats designed to fit.

XENO is an automated investment management platform that helps people to plan, save, and invest in their financial goals.

Xeno helps B2C brands run 1 to 1 marketing campaigns at scale to their existing customers. For example, we help a brand like Dunkin Donuts with 3 million customers create 3 million unique campaigns every couple of weeks. We help brands increase campaign conversions by more than 150%, while reducing the marketing manager's workload by 95%.

Xenogenix is an experienced and trusted Salesforce Consultancy Partner that uses a business process-focused approach to implement and develop cloud based sales, marketing and customer service solutions. We transform the way our clients do business and enable them to find, win and keep more customers. Xenogenix was launched in 2002 to provide business process and performance improvement consultancy services, identifying inefficiencies for our clients that were causing problems such as poor quality of service and resulting customer satisfaction and unnecessary costs. We became a Salesforce Partner in 2007 and believe it’s our understanding of business processes, the tools and techniques we apply before proposing a solution that continues to set us apart from other Salesforce Partners and which ultimately our clients benefit from. Since becoming a Partner we’ve completed projects for over 250 organisations, implementing, customising, developing and supporting solutions based on Salesforce and Force.com platform. Our clients, who range from small start-up businesses to multinational organisations, trust us to provide them with timely, high quality work and they return to us because we’re reliable, experienced and easy to work with.

Xenogenix is an experienced and trusted Salesforce Consultancy Partner that uses a business process-focused approach to implement and develop cloud based sales, marketing and customer service solutions. We transform the way our clients do business and enable them to find, win and keep more customers. Xenogenix was launched in 2002 to provide business process and performance improvement consultancy services, identifying inefficiencies for our clients that were causing problems such as poor quality of service and resulting customer satisfaction and unnecessary costs. We became a Salesforce Partner in 2007 and believe it’s our understanding of business processes, the tools and techniques we apply before proposing a solution that continues to set us apart from other Salesforce Partners and which ultimately our clients benefit from. Since becoming a Partner we’ve completed projects for over 250 organisations, implementing, customising, developing and supporting solutions based on Salesforce and Force.com platform. Our clients, who range from small start-up businesses to multinational organisations, trust us to provide them with timely, high quality work and they return to us because we’re reliable, experienced and easy to work with.

"Human-Friendly Technology"​ A spin-off company of the University of Tokyo. "人にやさしいデバイス"​ テクノロジーを社会に還元するために設立された、東大発ベンチャーです。

Who We Are: Xenon Pharmaceuticals (NASDAQ:XENE) is a neuroscience-focused biopharmaceutical company committed to discovering, developing, and commercializing innovative therapeutics to improve the lives of people living with neurological and psychiatric disorders. We are looking for great people who thrive in a respectful, collaborative, inclusive, and productive culture to join the Xenon team. What We Do: We are advancing an exciting product pipeline to address indications with high unmet medical need, including epilepsy and depression. Our flagship azetukalner program represents the most advanced potassium channel modulator in clinical development for multiple indications. Building upon the positive results and compelling data from our Phase 2b “X-TOLE” study in adult patients with focal epilepsy, our Phase 3 epilepsy program includes multiple clinical trials evaluating azetukalner in patients with focal onset seizures and primary generalized tonic-clonic seizures. In 2024, we are planning to initiate a Phase 3 azetukalner program in major depressive disorder, based on topline data from our Phase 2 “X-NOVA” clinical trial. In addition, we are proud of the leading-edge science coming out of our discovery labs, including early-stage research programs that leverage our extensive ion channel expertise and drug discovery capabilities to identify validated drug targets and develop new product candidates. Backed by a strong balance sheet to support our growth plans, we continue to build a fully integrated, premier neuroscience company with strong discovery, clinical development, corporate, and commercial operations.